Mostrando 10 resultados de: 16
Filtros aplicados
Publisher
Cancer Biology and Therapy(6)
Bionatura(2)
Cancers(1)
Clinical Nuclear Medicine(1)
Frontiers in Oncology(1)
Área temáticas
Enfermedades(16)
Farmacología y terapéutica(10)
Medicina y salud(2)
Cirugía y especialidades médicas afines(1)
Ginecología, obstetricia, pediatría, geriatría(1)
Origen
scopus(16)
Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile
ArticleAbstract: Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in thePalabras claves:Affinity, Avidity, Cancer immunotherapy, eGFR, monoclonal antibodies, nimotuzumab, Tumor targetingAutores:Fernandez L.E., Garrido G., Gracia E., Iznaga N., Kerbel R.S., Pérez R., Rabasa A., Tania Crombet, Tikhomirov I.A., Yang E.Fuentes:scopusAnti-epidermal growth factor/epidermal growth factor receptor therapeutic anti-cancer drugs and the wound healing process
ReviewAbstract: Cutaneous wound healing is a complex process involving blood clotting, inflammation, tissue formatioPalabras claves:CETUXIMAB, Cimavax, Erlotinib, Gefitinib, Her-1 vaccine, nimotuzumab, PanitimumabAutores:Casacó Parada A.R., Fernández A., Fuente D., Ledón N., Tania CrombetFuentes:scopusA pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.Fuentes:scopusA view on EGFR-targeted therapies from the oncogene-addiction perspective
ArticleAbstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen - a phenomenonPalabras claves:CETUXIMAB, Combination therapy, eGFR, Erlotinib, nimotuzumab, Oncogene addiction, Targeted therapyAutores:de Leon J., Moreno E., Pérez R., Tania CrombetFuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusEGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects
ReviewAbstract: Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guiPalabras claves:biological therapy, Cancer treatment, eGFR, nimotuzumab, Targeted therapyAutores:Garrido G., Moreno E., Pérez R., Tania CrombetFuentes:scopusNimotuzumab for Patients With Inoperable Cancer of the Head and Neck
ReviewAbstract: EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasisPalabras claves:eGFR, head and neck, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Iznaga-Escobar N., Mazorra Z., Mestre Fernández B., Tania CrombetFuentes:scopusNimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusNimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience
ArticleAbstract: Nimotuzumab, a humanized antibody targeting epidermal growth factor receptor, has potent anti-prolifPalabras claves:Anaplastic astrocytoma, glioblastoma multiforme, High grade glioma, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Alert J., Chon I., Jorrín E., Luaces P.L.o., Marinello J.J.u., Miranda N., Solomón M.T.e., Tania CrombetFuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopus